The case for & against
Bull & Bear analysis
Bearish
AngioDynamics, Inc. (NASDAQ: ANGO) is a leading medical technology company specializing in innovative medical devices for treatment in the areas of vascular access, oncology, and surgical specialty. With a strong emphasis on expanding its MedTech portfolio, AngioDynamics has reported a notable shift in revenue streams, with MedTech now accounting for nearly half of its total revenue. The company is well-positioned within the growing MedTech sector, focusing on advanced therapeutic solutions that leverage current technological trends within healthcare.
Bull says
- ↑MedTech segment grew 19% YoY, comprising 47% of total revenue
- ↑Projected gross margins of 54%–55% in fiscal 2027 support profitability
- ↑Shares rallied 33.5% over three months on growth optimism
- ↑Analyst revisions trending positive, signaling rising earnings outlook
- ↑High momentum indicates continued upward price trends
- ↑Strong balance sheet quality underpins resilience amid volatility
Bear says
- ↓Over 350 catheter lawsuits pose material financial and operational risk
- ↓Negative earnings outlook undermines returns amidst restructuring efforts
- ↓High short interest reflects broad investor skepticism
- ↓Valuation remains stretched despite operational headwinds
- ↓Weak profitability factor signals efficiency challenges
- ↓Elevated leverage increases vulnerability in economic downturns
Investment themes with ANGO
Medical Devices↓ -0.50%
Devices and instruments for medical treatment
ISRG · ABT · SYK
Earnings Call · Q3 2024 · Mgmt. Guidance
Updated 04-25-2025neutral
Transcript signals
Bull points
- solid pro forma revenue growth that we saw during our third quarter
- our third quarter of fiscal ’24 saw a return to double-digit year-over-year growth in our med tech segment and solid mid-single digit growth from our med device segment
- This expanded indication is a significant piece of the long term strategy that we laid out for you in July of 2021. It validates the unique design elements of our product and the significant benefit it provides to physicians and patients
Bear points
- Our mechanical thrombectomy business, which includes AngioVac and AlphaVac, declined roughly 12% year-over-year
- While AngioVac stabilized as we discussed last quarter, AlphaVac sales slowed due to a wind down at many of our sites as we completed enrolment in the APEX PE trial.
- We expect a continued softness in AlphaVac sales between the completion of the trial and the FDA approval of the PE indication.
Read full transcript analysis ›